Lipocalin 2 mediates appetite suppression during pancreatic cancer cachexia.

Autor: Olson B; Papé Family Pediatric Research Institute, Oregon Health & Science University, Portland, OR, USA.; Medical Scientist Training Program, Oregon Health & Science University, Portland, OR, USA., Zhu X; Papé Family Pediatric Research Institute, Oregon Health & Science University, Portland, OR, USA., Norgard MA; Papé Family Pediatric Research Institute, Oregon Health & Science University, Portland, OR, USA., Levasseur PR; Papé Family Pediatric Research Institute, Oregon Health & Science University, Portland, OR, USA., Butler JT; Papé Family Pediatric Research Institute, Oregon Health & Science University, Portland, OR, USA.; Medical Scientist Training Program, Oregon Health & Science University, Portland, OR, USA., Buenafe A; Papé Family Pediatric Research Institute, Oregon Health & Science University, Portland, OR, USA., Burfeind KG; Papé Family Pediatric Research Institute, Oregon Health & Science University, Portland, OR, USA.; Medical Scientist Training Program, Oregon Health & Science University, Portland, OR, USA., Michaelis KA; Papé Family Pediatric Research Institute, Oregon Health & Science University, Portland, OR, USA.; Medical Scientist Training Program, Oregon Health & Science University, Portland, OR, USA., Pelz KR; Brenden-Colson Center for Pancreatic Care, Oregon Health and & Science University, Portland, OR, USA., Mendez H; Brenden-Colson Center for Pancreatic Care, Oregon Health and & Science University, Portland, OR, USA., Edwards J; Papé Family Pediatric Research Institute, Oregon Health & Science University, Portland, OR, USA., Krasnow SM; Papé Family Pediatric Research Institute, Oregon Health & Science University, Portland, OR, USA., Grossberg AJ; Brenden-Colson Center for Pancreatic Care, Oregon Health and & Science University, Portland, OR, USA.; Department of Radiation Medicine, Oregon Health & Science University, Portland, OR, USA.; Cancer Early Detection Advanced Research Center, Knight Cancer Institute, Oregon Health & Science University, Portland, OR, USA., Marks DL; Papé Family Pediatric Research Institute, Oregon Health & Science University, Portland, OR, USA. marksd@ohsu.edu.; Brenden-Colson Center for Pancreatic Care, Oregon Health and & Science University, Portland, OR, USA. marksd@ohsu.edu.; Knight Cancer Institute, Oregon Health & Science University, Portland, OR, USA. marksd@ohsu.edu.

Publikováno v: Nature communications [Nat Commun] 2021 Apr 06; Vol. 12 (1), pp. 2057. Date of Electronic Publication: 2021 Apr 06.

The TLR7/8 agonist R848 remodels tumor and host responses to promote survival in pancreatic cancer.

Autor: Michaelis KA; Medical Scientist Training Program, Oregon Health & Science University, Portland, OR, USA.; Brenden-Colson Center for Pancreatic Care, Oregon Health & Science University, Portland, OR, USA., Norgard MA; Papé Family Pediatric Research Institute, Oregon Health & Science University, Portland, OR, USA., Zhu X; Papé Family Pediatric Research Institute, Oregon Health & Science University, Portland, OR, USA., Levasseur PR; Papé Family Pediatric Research Institute, Oregon Health & Science University, Portland, OR, USA., Sivagnanam S; Department of Computational Biology, Oregon Health & Science University, Portland, OR, USA., Liudahl SM; Department of Cell, Developmental and Cancer Biology, Knight Cancer Institute, Oregon Health & Science University, Portland, OR, USA., Burfeind KG; Medical Scientist Training Program, Oregon Health & Science University, Portland, OR, USA., Olson B; Medical Scientist Training Program, Oregon Health & Science University, Portland, OR, USA., Pelz KR; Papé Family Pediatric Research Institute, Oregon Health & Science University, Portland, OR, USA., Angeles Ramos DM; Papé Family Pediatric Research Institute, Oregon Health & Science University, Portland, OR, USA., Maurer HC; Departments of Medicine and Pathology and Cell Biology, Columbia University Medical Center, New York, NY, USA., Olive KP; Departments of Medicine and Pathology and Cell Biology, Columbia University Medical Center, New York, NY, USA., Coussens LM; Department of Cell, Developmental and Cancer Biology, Knight Cancer Institute, Oregon Health & Science University, Portland, OR, USA., Morgan TK; Department of Pathology, Oregon Health & Science University, Portland, OR, USA., Marks DL; Brenden-Colson Center for Pancreatic Care, Oregon Health & Science University, Portland, OR, USA. marksd@ohsu.edu.; Papé Family Pediatric Research Institute, Oregon Health & Science University, Portland, OR, USA. marksd@ohsu.edu.

Publikováno v: Nature communications [Nat Commun] 2019 Oct 15; Vol. 10 (1), pp. 4682. Date of Electronic Publication: 2019 Oct 15.

Activation of PP2A and Inhibition of mTOR Synergistically Reduce MYC Signaling and Decrease Tumor Growth in Pancreatic Ductal Adenocarcinoma.

Autor: Allen-Petersen BL; Department of Molecular and Medical Genetics, Oregon Health and Science University, Portland, Oregon., Risom T; Department of Molecular and Medical Genetics, Oregon Health and Science University, Portland, Oregon., Feng Z; Department of Cell, Developmental & Cancer Biology, Oregon Health and Science University, Portland, Oregon., Wang Z; Department of Molecular and Medical Genetics, Oregon Health and Science University, Portland, Oregon., Jenny ZP; Department of Molecular and Medical Genetics, Oregon Health and Science University, Portland, Oregon., Thoma MC; Department of Molecular and Medical Genetics, Oregon Health and Science University, Portland, Oregon., Pelz KR; Department of Molecular and Medical Genetics, Oregon Health and Science University, Portland, Oregon., Morton JP; CRUK Beatson Institute, Glasgow, Scotland, United Kingdom.; Institute of Cancer Sciences, University of Glasgow, Glasgow, Scotland, United Kingdom., Sansom OJ; CRUK Beatson Institute, Glasgow, Scotland, United Kingdom.; Institute of Cancer Sciences, University of Glasgow, Glasgow, Scotland, United Kingdom., Lopez CD; Department of Hematology and Oncology, Oregon Health and Science University, Portland, Oregon., Sheppard B; Department of Surgery, Oregon Health and Science University, Portland, Oregon., Christensen DJ; Oncotide Pharmaceuticals, Inc., Research Triangle Park, North Carolina., Ohlmeyer M; Icahn School of Medicine at Mount Sinai, New York, New York., Narla G; School of Medicine, Case Western Reserve University, Cleveland, Ohio., Sears RC; Department of Molecular and Medical Genetics, Oregon Health and Science University, Portland, Oregon. searsr@ohsu.edu.

Publikováno v: Cancer research [Cancer Res] 2019 Jan 01; Vol. 79 (1), pp. 209-219. Date of Electronic Publication: 2018 Nov 02.